Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratories [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
High-throughput efficiency, with up to 2,000 tests per hour on cobas® c 703 and up to 70 reagent positions for testing optimization. The new cobas® ISE neo analytical unit delivers up to 1,800 tests per hour and reduces hands-on time through automated maintenance. INDIANAPOLIS March 30, 2026 /PRNewswire/ -- Roche announced today the U.S. Food and Drug Administration (FDA) 510(k) clearance of its newest analytical units – the cobas® c 703 and cobas® ISE neo. As part of the scalable and modular cobas® pro integrated solutions, these additions deliver advanced lab-automation capabilities designed to help address some of today's most pressing laboratory challenges, including staff shortages, limited space and growing test volumes. Roche Logo (PRNewsfoto/Roche) "Laboratories are the indispensable engine of modern healthcare, and Roche wants to partner in addressing staffing-shortage challenges and an ever-increasing demand for testing," said Brad Moore, President and CEO of Roche
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Target RWE Strengthens Leadership Team with Appointments Across Delivery, Finance and Commercial [Yahoo! Finance]Yahoo! Finance
- Adrenocortical Carcinoma Market Report 2026: Innovative Therapies Set to Transform the $4 Billion Adrenocortical Carcinoma Landscape [Yahoo! Finance]Yahoo! Finance
- Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma [TheStreet.com]TheStreet.com
- Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform [Yahoo! Finance]Yahoo! Finance
- Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratoriesPR Newswire